Thrombogenics NV, of Leuven, Belgium, said preclinical data published in Experimental Eye Research testing the murine form of THR-317 in various animal models of diabetic retinopathy (DR) showed that the anti-PlGF antibody shared a common pharmacology toward vascular leakage in comparison to VEGF inhibitors, which are currently the standard of care for DR.